鹽酸達(dá)利雷生 Daridorexant Hydrochloride
【化學(xué)名】Daridorexant Hydrochloride
【原研】Actelion
【上市時(shí)間】2022年01月07日
【用途】用于治療入睡和睡眠障礙。
【劑型/規(guī)格】口服片劑，規(guī)格是EQ 50MG BASE; EQ 25MG BASE
鹽酸達(dá)利雷生Daridorexant Hydrochloride
一、產(chǎn)品概述
鹽酸達(dá)利雷生是由Actelion Pharmaceuticals Ltd研發(fā)的一種小分子藥物，于2022年01月07日獲得美國(guó)食品藥品管理局FDA批準(zhǔn)，用于治療入睡和睡眠障礙。
二、主要產(chǎn)品
Description | Structural Formula | CAS No. | Category |
Daridorexant Hydrochloride |
| 1792993-84-0 | API |
4-Chloro-3-Methylbenzene-1,2-diaMine hydrochloride |
| 1087743-89-2 | intermediates |
2-Methyl-L-proline Methyl ester hydrochloride |
| 220060-08-2 | intermediates |
5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid |
| 1293284-55-5 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.